文献速递胸部肿瘤放疗

局限期小细胞肺癌的心脏死亡率

Cardiac mortality in limited-stage small cell lung cancer.
PubMed 文献 · Radiother Oncol · 2018-06-19

该研究利用监测、流行病学和最终结果数据库,比较接受放疗的I-III期原发性小细胞肺癌患者中左侧与右侧病变的心脏特异性死亡率(CSM),发现左侧患者CSM显著更高(3.3% vs. 2.6%,p=0.004),偏侧性为CSM独立预测因素(HR 1.27,95%CI 1.08-1.50),但与非心脏死亡率无统计学关联。

要点

  • 左侧局限期小细胞肺癌患者心脏特异性死亡率显著高于右侧(3.3% vs. 2.6%,p=0.004)。
  • 偏侧性是心脏特异性死亡的独立预测因素(HR 1.27,95%CI 1.08-1.50)。
  • 偏侧性与非心脏死亡率无统计学关联(Fine和Gray竞争风险模型p=0.130)。

核心结论

  • 基于这些数据无法断言放疗与局限期小细胞肺癌心脏特异性死亡率之间的因果关系,但作者鼓励临床关注心脏保护性放疗,并进一步研究心脏毒性的剂量学相关因素。

研究设计与样本

  • 回顾性数据库研究,查询监测、流行病学和最终结果数据库,纳入接受放疗的I-III期原发性小细胞肺癌患者,比较左侧与右侧病变的心脏特异性死亡率。

主要发现

  • 在19,692例患者中,左侧7,991例(41%),右侧11,701例(59%)。
  • 左侧患者心脏特异性死亡率总体显著更高(3.3% vs. 2.6%,p=0.004)。
  • 偏侧性在Fine和Gray竞争风险模型(p=0.006)及Cox比例风险模型(p=0.007)中均为心脏特异性死亡率的独立预测因素。
  • 按疾病偏侧性计算的心脏特异性死亡率总体风险比为1.27(95%CI 1.08-1.50)。
  • 偏侧性与非心脏死亡率无统计学关联(Fine和Gray竞争风险模型p=0.130)。

关键数值与推荐

  • 左侧患者心脏特异性死亡率3.3% vs. 右侧2.6%(p=0.004)。
  • 偏侧性预测心脏特异性死亡率的总体风险比HR 1.27(95%CI 1.08-1.50)。
  • Fine和Gray竞争风险模型中偏侧性预测心脏特异性死亡率p=0.006。
  • Cox比例风险模型中偏侧性预测心脏特异性死亡率p=0.007。
  • Fine和Gray竞争风险模型中偏侧性与非心脏死亡率关联p=0.130。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Life expectancy of patients with limited-stage small cell lung cancer (LS-SCLC) continues to rise; thus, characterization of long-term toxicities is essential. Although there are emerging data linking cardiac irradiation doses with survival for non-small cell lung cancer, there are currently minimal data on cardiac-specific mortality (CSM) in LS-SCLC. The goal of this investigation was to evaluate CSM between left- and right-sided cases. METHODS: The Surveillance, Epidemiology, and End Results database was queried for stage I-III primary SCLC patients receiving radiotherapy; CSM was compared between left- and right-sided diseases. Accounting for mortality from other causes, Gray's test compared cumulative incidences of CSM between both groups. Multiple multivariate models examined the independent effect of laterality on CSM, including the Fine and Gray competing risk model and the Cox proportional hazards model. RESULTS: Of 19,692 patients, 7991 (41%) were left-sided and 11,701 (59%) were right-sided. Left-sided patients experienced significantly higher CSM overall (3.3% vs. 2.6%, p = 0.004). Laterality was an independent predictor of CSM in the overall population in the Fine and Gray competing risk model (p = 0.006) as well as the Cox proportional hazards model (p = 0.007). The overall hazard ratio for CSM by disease laterality was 1.27 (95% confidence interval, 1.08-1.50). Laterality had no statistical association with non-cardiac mortality in the Fine and Gray competing risk model (p = 0.130). CONCLUSIONS: Although causation between radiotherapy and CSM in LS-SCLC cannot be stated based on these data, we encourage clinical attentiveness to cardiac-sparing radiotherapy for LS-SCLC, along with further investigation evaluating dosimetric correlates for cardiotoxicity.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Verma V, Fakhreddine MH, Haque W, et al. Cardiac mortality in limited-stage small cell lung cancer. Radiother Oncol. 2018. PMID: 29934110. doi:10.1016/j.radonc.2018.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。